Vnitr Lek 2015, 61(11):933-935

Stanovisko k nové moderní hypolipidemické léčbě

Richard Češka1,*, Miloš Táborský2, Michal Vrablík1
1 Centrum preventivní kardiologie III. interní kliniky 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
2 I. interní klinika - kardiologická LF UP a FN Olomouc, přednosta prof. MUDr. Miloš Táborský, CSc., FESC, FACC, MBA

Received: October 8, 2015; Published: November 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R, Táborský M, Vrablík M. Stanovisko k nové moderní hypolipidemické léčbě. Vnitr Lek. 2015;61(11):933-935.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reiner Z, Catapano AL, De BG et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769-1818. Go to original source... Go to PubMed...
    2. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670-1681. 1. Go to original source... Go to PubMed...
    3. Mihaylova B, Emberson J, Blackwell L et al. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581-590. Go to original source... Go to PubMed...
    4. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816. Go to original source... Go to PubMed...
    5. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563-1574.. Go to original source... Go to PubMed...
    6. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-3490.. Go to original source... Go to PubMed...
    7. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015; 372: 1500-1509. Go to original source... Go to PubMed...
    8. Koren MJ, Lundqvist P, Bolognese M et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial ofevolocumab. J Am Coll Cardiol 2014; 63: 2531-2540. Go to original source... Go to PubMed...
    9. Robinson JG, Nedergaard BS, Rogers WJ et al. Effect of evolocumab or ezetimibe added to moderate orhigh-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. The LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870-1882. Go to original source... Go to PubMed...
    10. Raal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331-340. Go to original source... Go to PubMed...
    11. Stroes E, Colquhoun D, Sullivan D et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial ofevolocumab. J Am Coll Cardiol 2014; 63: 2541-2548. Go to original source... Go to PubMed...
    12. Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 341-350. Go to original source... Go to PubMed...
    13. Blom DJ, Hala T, Bolognese MA 52-week placebo-controlled trial ofevolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-1819. Go to original source... Go to PubMed...
    14. Koren MJ, Giugliano RP, Raal FJ et al. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation 2014; 129: 234-243. Go to original source... Go to PubMed...
    15. Jennifer G, Robinson MD, Farnier M et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015; 372: 1489-1499. Go to original source... Go to PubMed...
    16. Moriarty PM, Jacobson TA, Buckert E et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2012; 8: 554-561. Go to original source... Go to PubMed...
    17. Stone NJ, Lloyd-Jones DM Lower LDL cholesterol is better, but it matter show youget there, and in whom. N Engl J Med 2015 Mar 15; [epub]. http://dx.doi.org/10.1056/NEJMe1502192).
    18. Kastelein JJ, Robinson JG, FarnierM et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-loweringt herapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther 2014; 28: 281-289. Go to original source... Go to PubMed...
    19. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to
    20. Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387-2397. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.